Program
atisnolerbart
Its studies are mostly in Rhinitis, Allergic · Conjunctivitis, Allergic, led by Regeneron Pharmaceuticals.
Furthest: phase 3, since Dec 23, 20203 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 30 open or running | phase 3since Dec 23, 2020 | Dec 23, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 23, 2020First study: phase 3 study in Rhinitis, AllergicFirst studyNCT04709575 · 353 enrolled · United States, Belgium, Canada and more
- Jun 20, 2022Phase 2 study in Rhinitis, AllergicNCT05430919 · 217 enrolled · Canada
- Dec 17, 2025Phase 3 study in Conjunctivitis, AllergicNCT07309432 · 24 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07309432Conjunctivitis, Allergic · United States | 3 | Terminated | May 2, 2026 | 24 |
| NCT05430919Rhinitis, Allergic · Canada | 2 | Completed | Jul 31, 2023 | 217 |
| NCT04709575Rhinitis, Allergic · United States, Belgium, Canada and more | 3 | Completed | Aug 24, 2021 | 353 |
How it is read
Names in the registry
- “REGN5715”, 3 entries
Conditions, from the studies’ own filings
- Rhinitis, Allergic, 2 studies
- Conjunctivitis, Allergic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.